Clinical trials: MASLD
NAFLD, MASLD
NAFLD Clinical Care Pathway
Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrhosis, liver failure and liver cancer.
- Trial name
- NCCP (NCT06671886)
- Testing
- E-trigger
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatocellular Carcinoma
Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH
The BOMASH study is a single-center, prospective/retrospective observational study without pharmacological interventions. It will include all patients diagnosed with Metabolic-Associated Steatotic Liver Disease (MASLD/MASH)…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatocellular Carcinoma, Metabolic Dysfunction-Associated Steatohepatitis, Liver Transplant
- Trial name
- BOMASH (NCT06813508)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Type 2 Diabetes Mellitus (T2DM), Metabolic Dysfunction-Associated Steatotic Liver Disease
Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Metabolic Dysfunction-Associated Steatotic Liver Disease, Biological Age
- Trial name
- NCT06984510
- Testing
- Observational
- Where
- China
- Volunteers
- 2,720 people
- Sponsor
- Ningbo No. 1 Hospital
MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Quantitative Ultrasound to Assess Steatotic Liver Disease in Children
This research study is being conducted to find out more about advanced ultrasound techniques to non-invasively evaluate liver disease in children.
- Trial name
- NCT06706856
- Testing
- MR exam, US exam, Blood draw
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of California, San Diego
Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
The purpose of this study is to evaluate the efficacy and safety of a short-term (12-week) prehabilitation strategy combining mazdutide (a novel GLP-1/GCG receptor dual agonist) with lifestyle optimization, compared to lifestyle…
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis, Living Liver Donors
- Trial name
- PRIME (NCT07718126)
- Testing
- Mazdutide, Lifestyle Optimization
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- West China Hospital
MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Study of Resmetirom in Children and Adolescents With MASH
This study will evaluate the safety, pharmacokinetics (how the body absorbs, distributes, metabolizes, and eliminates the drug), and pharmacodynamics (how the drug affects the body) of resmetirom in children and adolescents with…
- Trial name
- NCT07763015
- Testing
- Resmetirom
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Study on Risk Factors and Prognosis of MASLD
This longitudinal cohort study will enroll individuals with MASLD (and/or those at risk) and follow them over time to identify clinical and metabolic risk factors for disease progression and to evaluate predictors of long-term…
- Trial name
- NCT07433205
- Where
- China
- Volunteers
- 922 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Diabetes Mellitus
Effect of Sinbiotic With Multispecies Probiotics on Liver Parameters Liver Enzymes, Ultrasound, Elastography and Adipokines in Same Cases) in Patients With Metabolic Associated Steatotic Liver Disease.
Scientific hypothesis: the use of a synbiotic preparation with a multi-strain probiotic in patients with MASLD can lead to a decrease in non-invasive elastographic parameters of hepatic steatosis and fibrosis and an improvement…
- Conditions
- MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Diabetes Mellitus, Hypertension, Hyperlipidaemia
- Trial name
- NCT07025980
- Testing
- The test product is a ready-to-use sinbiotic preparation of multispecies probiotics, ca-butyrate and FOS
- Where
- Croatia
- Volunteers
- 114 people
- Sponsor
- Eva Cubric
Heterozygous Familial Hypercholesterolemia
Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia
The main goal of the STEATO-FH study is to determine the prevalence of liver steatosis within the Heterozygous Familial Hypercholesterolemia patient population.
- Trial name
- STEATO-FH (NCT06634160)
- Testing
- Fibroscan, Sample collection
- Where
- 3 sites in France
- Volunteers
- 200 people
- Sponsor
- Nantes University Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease
Effects of Short-term Perioperative Daidzein Intervention on Liver Histopathology in Patients With MASLD
This clinical trial aims to learn whether daidzein can improve liver tissue changes in adults with metabolic dysfunction-associated steatotic liver disease, also called MASLD.
- Trial name
- DAIMAS (NCT07623044)
- Testing
- Daidzein
- Volunteers
- 44 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
HCC - Hepatocellular Carcinoma
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
This research plan involves a treatment approach for advanced hepatocellular carcinoma (HCC) in the context of metabolic-associated steatotic liver disease (MASLD).
- Trial name
- ABATE-MASLD (NCT07285850)
- Testing
- Sequential treatment of bevacizumab combined with atezolizumab (sequential group), Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD)
Time-restricted Feeding in MASLD
The recommended treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) currently focuses on lifestyle changes, including dietary adjustments and increased physical activity.
- Trial name
- MASLD-Interval (NCT07530809)
- Testing
- time-restricted feeding in a 5:2 regimen
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Universität des Saarlandes
Liver Disease
Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians
This study is a cross-sectional survey-based study. The main goal of this study is to investigate the attitudes, perceptions, and clinical practice in assessing liver fibrosis following a metabolic dysfunction-associated…
- Trial name
- NCT07682363
- Testing
- No treatment is given
- Where
- China
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
MASLD
A Study of Electronic Clinical Decision Support Tools for Steatotic Liver Disease
The overall objectives of this study are to determine the effectiveness of a participant-specific guided electronic decision support system on provider decision making for participants with metabolic-dysfunction associated…
- Trial name
- eMPOWER (NCT07382349)
- Testing
- eMPOWER Decision Aid
- Where
- United States
- Volunteers
- 7,200 people
- Sponsor
- Vanderbilt University Medical Center
Sarcopenia Among Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
Sarcopenia Among Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
Determination of sarcopenia frequency among patients with metabolic dysfunction-associated steatotic liver disease 2- Exploring the association of sarcopenia with disease state (steatosis grade and fibrosis) among patients with…
- Trial name
- NCT07598916
- Volunteers
- 120 people
- Sponsor
- Assiut University
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease
Fibrosis Lessens After Metabolic Surgery
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis
- Trial name
- FLAMES (NCT06374875)
- Testing
- Metabolic surgery, Incretin-Based Therapy
- Where
- 22 sites in United States, Brazil and 11 more
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Food Insecurity Among Children
Food Insecurity and MASLD: A Fruit and Vegetable Intervention Study
This proposal addresses a critical gap in the understanding of the impact of household food insecurity (FI) on pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) severity.
- Trial name
- NCT07091539
- Testing
- Fruit/vegetable vouchers
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of California, San Francisco
HCC, MASLD
Accumulation of Lipid Droplets as an Underlying Cause of the Progression of Fatty Liver Disease to Liver Cancer
Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently the leading cause of chronic liver disease, accounting for an increasing burden of cirrhosis, hepatocellular carcinoma (HCC), and related mortality…
- Trial name
- NCT07775716
- Testing
- Comprehensive Genomic and Transcriptomic Profiling, Patient-Derived Human Liver Organoid (HLO) Development, AI-Driven Digital Pathology (HistoIndex)
- Where
- Italy
- Volunteers
- 35,500 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Metabolic Dysfunction-associated Steatotic Liver Disease
Fecal Microbiota Analysis of PNPLA3 Polymorphism in Hispanic Patients With MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of liver disease worldwide. The condition is defined by fat accumulation exceeding 5% of liver weight not explained by at-risk alcohol…
- Trial name
- MPM (NCT06495333)
- Where
- Puerto Rico
- Volunteers
- 100 people
- Sponsor
- Fundacion de Investigacion Science and Education
Type 2 Diabetes
A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)
This study aims to compare the effect of two drugs used to treat diabetes, that is, Dapagliflozin and Empagliflozin on HbA1c (which is an indicator of blood sugar over the last 3 months) body weight, liver and kidney function…
- Trial name
- NCT07311551
- Testing
- Dapagliflozin (10Mg Tab) along with standard medical therapy, Empagliflozin (25 Mg Tab) along with standard medical therapy
- Volunteers
- 112 people
- Sponsor
- Bhavya Bhavya, MD